Patents by Inventor Michael John Mullan

Michael John Mullan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090203033
    Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
    Type: Application
    Filed: April 24, 2009
    Publication date: August 13, 2009
    Inventor: MICHAEL JOHN MULLAN
  • Patent number: 7538258
    Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: May 26, 2009
    Assignee: Alzheimer's Institute of America, Inc.
    Inventor: Michael John Mullan
  • Patent number: 6818448
    Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: November 16, 2004
    Assignee: Alzheimer's Institute of America, Inc.
    Inventor: Michael John Mullan
  • Publication number: 20030165958
    Abstract: Model systems of Alzheimer's disease comprise a DNA sequence encoding an amyloid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding to amino acid residue position 717 of APP770. Methods of determining genetic predisposition to Alzheimer's disease are also disclosed.
    Type: Application
    Filed: February 3, 2003
    Publication date: September 4, 2003
    Applicant: Elan Pharmaceuticals
    Inventors: John Anthony Hardy, Marie-Christine Chartier-Harlin, Alison Mary Goate, Michael John Owen, Michael John Mullan
  • Publication number: 20020133834
    Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
    Type: Application
    Filed: February 16, 2001
    Publication date: September 19, 2002
    Applicant: Alzheimer's Institute of America, Inc.
    Inventor: Michael John Mullan
  • Patent number: 6300540
    Abstract: Model systems of Alzheimer's disease comprise a DNA sequence encoding an amyloid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding to amino acid residue position 717 of APP770. Methods of determining genetic predisposition to Alzheimer's disease are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 9, 2001
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: John Anthony Hardy, Marie-Christine Chartier-Harlin, Alison Mary Goate, Michael John Owen, Michael John Mullan
  • Patent number: 5877015
    Abstract: Model systems of Alzheimer's disease comprise a DNA sequence encoding an amyloid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding to amino acid residue position 717 of APP770. Methods of determining genetic predisposition to Alzheimer's disease are also disclosed.
    Type: Grant
    Filed: January 21, 1992
    Date of Patent: March 2, 1999
    Assignee: Imperial College of Science, Technology of Medicine
    Inventors: John Anthony Hardy, Marie-Christine Chartier-Harlin, Alison Mary Goate, Michael John Owen, Michael John Mullan
  • Patent number: 5795963
    Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: August 18, 1998
    Assignee: Alzheimer's Institute of America
    Inventor: Michael John Mullan